Literature DB >> 28592115

Identification of chemokine CXCL10 in tumor microenvironment by antibody array as a prognostic marker in hepatocellular carcinoma.

L Li, Y H Zhu, Y Li, X Y Guan.   

Abstract

Immunological microenvironment is not only composed of multiple immune cells, but also deposited various inflammation factors that regulate immune response to tumor cells. To ascertain the crucial immune factors presented in hepatocellular carcinoma microenvironment (HCM), tumor tissue culture supernatant (TCS) and the corresponding non-tumor tissue culture supernatant (NCS) from patient with hepatocellular carcinoma (HCC) were analyzed by antibody array technology. Among the inflammation-associated cytokines assayed, high level of chemokines CXCL8/IL-8 (6.82-fold increase) and CXCL10/IP-10 (16.45-fold increase) in TCS than that in paired NCS were evidently identified. And low expression of IL-16 (0.14-fold decrease) and RANTES/CCL5 (0.17-fold decrease) in TCS were also uncovered. Especially, overexpression of CXCL10 in primary HCC compared with their non-tumor counterparts was significantly associated with serum AFP level (P = 0.004), tumor size (P = 0.021), tumor number (P < 0.001) and TNM stage (P = 0.027). In addition, Kaplan-Meier curves demonstrated that patients with higher CXCL10 expression levels had significantly poorer overall survival (P = 0.016) and disease-free survival (P = 0.022) than those with lower CXCL10 expression levels. Univariate and multivariate analyses revealed that the level of CXCL10 expression was an independent prognostic factor for overall survival in HCC patients. In summary, high concentration of CXCL10 is deposited in HCM identified by antibody array, which may contribute to the prediction of clinical outcome of HCC patients.

Entities:  

Keywords:  CXCL10; hepatocellular carcinoma; tissue culture antibody array.; tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28592115     DOI: 10.4149/neo_2017_517

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer.

Authors:  Mingyi Ju; Longyang Jiang; Qian Wei; Lifeng Yu; Lianze Chen; Yan Wang; Baohui Hu; Ping Qian; Ming Zhang; Chenyi Zhou; Zinan Li; Minjie Wei; Lin Zhao; Jiali Han
Journal:  Onco Targets Ther       Date:  2021-10-20       Impact factor: 4.147

Review 2.  Chemokines and the immune response to cancer.

Authors:  Aleksandra J Ozga; Melvyn T Chow; Andrew D Luster
Journal:  Immunity       Date:  2021-04-10       Impact factor: 31.745

3.  Role of chemokines in hepatocellular carcinoma (Review).

Authors:  Dongdong Xue; Ya Zheng; Junye Wen; Jingzhao Han; Hongfang Tuo; Yifan Liu; Yanhui Peng
Journal:  Oncol Rep       Date:  2020-12-22       Impact factor: 3.906

4.  Serum Levels of CXCL13 Are an Independent Predictor of Survival Following Resection of Biliary Tract Cancer.

Authors:  Sven H Loosen; Tom F Ulmer; Simon Labuhn; Jan Bednarsch; Sven A Lang; Patrick H Alizai; Anne T Schneider; Mihael Vucur; Ulf P Neumann; Tom Luedde; Christoph Roderburg
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

5.  Identification of Biomarkers Associated with Liver Metastasis Progression from Colorectal Cancer Using Exosomal RNA Profiling.

Authors:  Soohyeon Lee; Young Soo Park; Jwa Hoon Kim; Ah Reum Lim; Myung Han Hyun; Boyeon Kim; Jong Won Lee; Saet Byeol Lee; Yeul Hong Kim
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

6.  CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma.

Authors:  Jingya Zhang; Dong Dong; Qian Wei; Li Ren
Journal:  BMC Cancer       Date:  2022-10-08       Impact factor: 4.638

7.  High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.

Authors:  Lei Li; Yong-Dong Liu; Yu-Ting Zhan; Ying-Hui Zhu; Yan Li; Dan Xie; Xin-Yuan Guan
Journal:  Thorac Cancer       Date:  2018-05-02       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.